Afatinib Recruiting Phase 2 Trials for Lung Cancers Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01553942Afatinib With CT and RT for EGFR-Mutant NSCLC